Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): Updated results of a phase II study
Publication
, Conference
George, DJ; Corn, PG; Michaelson, MD; Hammers, HJ; Alumkal, JJ; Ryan, CJ; Bruce, JY; Moran, S; Lee, S-Y; Mortimer, P; Hussain, M
Published in: JOURNAL OF CLINICAL ONCOLOGY
May 20, 2012
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2012
Volume
30
Issue
15
Location
Chicago, IL
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
George, D. J., Corn, P. G., Michaelson, M. D., Hammers, H. J., Alumkal, J. J., Ryan, C. J., … Hussain, M. (2012). Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): Updated results of a phase II study. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 30). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
George, Daniel J., Paul G. Corn, M Dror Michaelson, Hans J. Hammers, Joshi J. Alumkal, Charles J. Ryan, Justine Yang Bruce, et al. “Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): Updated results of a phase II study.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
George DJ, Corn PG, Michaelson MD, Hammers HJ, Alumkal JJ, Ryan CJ, et al. Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): Updated results of a phase II study. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2012.
George, Daniel J., et al. “Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): Updated results of a phase II study.” JOURNAL OF CLINICAL ONCOLOGY, vol. 30, no. 15, AMER SOC CLINICAL ONCOLOGY, 2012.
George DJ, Corn PG, Michaelson MD, Hammers HJ, Alumkal JJ, Ryan CJ, Bruce JY, Moran S, Lee S-Y, Mortimer P, Hussain M. Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): Updated results of a phase II study. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2012.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2012
Volume
30
Issue
15
Location
Chicago, IL
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences